Interleukin-7 receptor alpha (IL-7Rα) (IL-7R)

The Interleukin-7 receptor alpha (IL-7Rα), or CD127, is a vital component of the IL-7 receptor complex that regulates T-cell development and survival. In advanced immunotherapy, a constitutively active version of this receptor (C7R) is engineered into Epstein-Barr Virus (EBV)-specific T cells to overcome the limitations of the tumor microenvironment. This modified receptor utilizes specific mutations to signal independently of the IL-7 ligand, ensuring the T cells receive constant survival cues via the JAK/STAT5 pathway. This approach is particularly relevant for treating EBV-associated malignancies, such as Hodgkin lymphoma and post-transplant lymphoproliferative disorders, where endogenous cytokine support is often insufficient. By enhancing the persistence and metabolic fitness of adoptive T-cell therapies, the constitutively active IL-7 receptor serves as a potent tool to improve clinical outcomes in refractory cancers. However, the potential for uncontrolled cellular proliferation necessitates rigorous safety monitoring and the inclusion of safety switches in clinical applications.

Other names

CD127IL7RAC7RConstitutively active IL-7 receptorInterleukin-7 receptor subunit alphaCDw127

The constitutively active interleukin-7 receptor (C7R) functions by bypassing the requirement for the IL-7 ligand through engineered mutations, such as a cysteine insertion in the extracellular or transmembrane domain, which facilitates stable disulfide-linked homodimerization. This dimerization leads to the continuous activation of the Janus kinase (JAK) and Signal Transducer and Activator of Transcription 5 (STAT5) signaling pathways. In engineered EBV-specific T cells, this provides autonomous survival and proliferative signals, allowing the cells to persist and maintain anti-tumor activity within the immunosuppressive and cytokine-depleted tumor microenvironment.